Abstract 1763: Efficacy of the Generation-2 Acorn Cardiac Support Device in Dogs with Chronic Heart Failure
Background: We previously showed that long-term therapy with the first generation (Gen-1) CorCap™ Cardiac Support Device (CSD, Acorn Cardiovascular, Inc.) improved left ventricular (LV) function and reversed progressive LV remodeling in dogs with chronic heart failure (HF). In the present study, we examined the effects of a redesigned generation-2 (Gen-2) CSD in the same dog model of chronic HF (LV EF<40%). The Gen-2 CSD is a self-fitting polyester mesh that does not require suture anchoring to the atrio-ventricular groove nor tailoring of an anterior seam for proper fit and is designed to be implanted using a minimally invasive surgical approach (2.5 inch thoracotomy).
Methods: In this study, 17 dogs with intracoronary microembolization-induced HF were randomized to receive either the Gen-1 CSD (n=6), the Gen-2 CSD (n=6) or to no CSD at all (Control, n=5). All dogs were followed for 90 days. LV end-diastolic volume (EDV), end-systolic volume (ESV), and EF were measured from ventriculograms before implantation of the CSD (PRE) and 90 days after implantation (POST). The extent of encapsulation of the CSD by connective tissue (thickness of the CSD + connective tissue, THK) was examined histomortphometrically at end of study.
Results: Data are shown in the table⇓. As expected EDV and ESV increased and EF decreased in Controls. Treatment with either the Gen-1 or Gen-2 afforded similar reductions of EDV and ESV and similar increases of EF. The average THK was the same in both groups (0.60 ± 0.01 mm).
Conclusions: In dogs with chronic HF, monotherapy with the Gen-2 CSD is as effective as the Gen-1 CSD in improving LV function and preventing progressive LV dilation. The Gen-2 CSD, however, is easier to implant, avoids the need for suture anchoring and eliminates intra-operative surgical fitting and can be implanted minimally-invasively through a small thoracotomy.